 |
|
National Trends in Cyclooxygenase-2 Inhibitor Use Since Market Release
Nonselective Diffusion of a Selectively Cost-effective Innovation
Carolanne Dai, BSc, MSc;
Randall S. Stafford, MD, PhD;
G. Caleb Alexander, MD, MS
Arch Intern Med. 2005;165:171-177.
Background The withdrawal of rofecoxib has highlighted concerns regarding the safety of cyclooxygenase-2 (COX-2) inhibitors. In some patients COX-2 inhibitors may be safer than nonselective nonsteroidal anti-inflammatory drugs (NSAIDs); however, the public health benefit of COX-2 inhibitors depends on their use in patients at higher than normal risk from NSAIDs. We examined trends in COX-2 inhibitor use based on risk for adverse events from NSAIDs.
Methods We analyzed data from the National Ambulatory Medical Care Survey (1999-2002) and National Hospital Ambulatory Medical Care Survey (1999-2001), nationally representative surveys of community and hospital-based outpatient practices. The main outcome measure was the proportion of patient visits in which COX-2 inhibitors were prescribed, stratified by risk of adverse gastrointestinal (GI) events from NSAIDs.
Results Of the visits in which either a COX-2 inhibitor or NSAID was prescribed, the frequency of COX-2 inhibitor use increased from 35% (1999) to 55% (2000) to 61% (2001 and 2002). Among patients with the lowest risk for adverse events from NSAIDs, the proportion receiving a COX-2 inhibitor increased from 12% in 1999 to 35% in 2002. Overall, increases in COX-2 inhibitor use among patients in whom NSAIDs could be used accounted for more than 63% of the growth in COX-2 inhibitor use during the period examined.
Conclusions Marked increases in COX-2 inhibitor use have occurred since their release, primarily among patients at low risk for adverse events from NSAIDs. These findings demonstrate the challenge of limiting innovative therapies to the settings in which they are initially targeted and maximally beneficial.
Author Affiliations: Harris School of Public Policy Studies (Ms Dai) and the Robert Wood Johnson Clinical Scholars Program and MacLean Center for Clinical Medical Ethics (Dr Alexander), The University of Chicago, Chicago, Ill; Stanford Prevention Research Center, Stanford University, Stanford, Calif (Dr Stafford); and the Department of Internal Medicine, University of Chicago Hospitals, Chicago (Dr Alexander).
RELATED ARTICLES
Coxibs, Science, and the Public Trust
Daniel H. Solomon and Jerry Avorn
Arch Intern Med. 2005;165(2):158-160.
EXTRACT
| FULL TEXT
The Effects of Cyclooxygenase-2 Inhibitors and Nonsteroidal Anti-inflammatory Therapy on 24-Hour Blood Pressure in Patients With Hypertension, Osteoarthritis, and Type 2 Diabetes Mellitus
James R. Sowers, William B. White, Bertram Pitt, Andrew Whelton, Lee S. Simon, Nathaniel Winer, Alan Kivitz, Hein van Ingen, Thomas Brabant, John G. Fort, and for the Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators
Arch Intern Med. 2005;165(2):161-168.
ABSTRACT
| FULL TEXT
Selective Cyclooxygenase-2 Inhibition and Cardiovascular Effects: An Observational Study of a Medicaid Population
Fadia T. Shaya, Steven W. Blume, Christopher M. Blanchette, Matthew R. Weir, and C. Daniel Mullins
Arch Intern Med. 2005;165(2):181-186.
ABSTRACT
| FULL TEXT
Risk of Upper Gastrointestinal Hemorrhage in Warfarin Users Treated With Nonselective NSAIDs or COX-2 Inhibitors
Marisa Battistella, Muhammad M. Mamdami, David N. Juurlink, Linda Rabeneck, and Andreas Laupacis
Arch Intern Med. 2005;165(2):189-192.
ABSTRACT
| FULL TEXT
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Regulating Off-Label Drug Use -- Rethinking the Role of the FDA
Stafford
NEJM 2008;358:1427-1429.
FULL TEXT
What is the harm-benefit ratio of Cox-2 inhibitors?
van Staa et al.
Int J Epidemiol 2008;37:405-413.
ABSTRACT
| FULL TEXT
Are We Ignoring the Elephant in the Room?
Jindeel
Arch Intern Med 2007;167:2263-2264.
FULL TEXT
GI Risk Factors and Use of GI Protective Agents Among Patients Receiving Nonsteroidal Antiinflammatory Drugs
Harris et al.
The Annals of Pharmacotherapy 2006;40:1924-1931.
ABSTRACT
| FULL TEXT
Risks versus benefits of cyclooxygenase-2-selective nonsteroidal antiinflammatory drugs.
Chaiamnuay et al.
Am J Health Syst Pharm 2006;63:1837-1851.
ABSTRACT
| FULL TEXT
The Lessons of Vioxx -- Drug Safety and Sales
Waxman
NEJM 2005;352:2576-2578.
FULL TEXT
Benefits of early invasive treatment for acute coronary syndromes: lost in translation?
Green
BMJ 2005;330:E351-E352.
FULL TEXT
Are Cyclooxygenase-2 Inhibitors Being Taken Only by Those Who Need Them?
Kaufman et al.
Arch Intern Med 2005;165:1066-1067.
FULL TEXT
Direct-to-Consumer Advertising: A Haphazard Approach to Health Promotion
Hollon
JAMA 2005;293:2030-2033.
FULL TEXT
More Data on COX-2 Inhibitors
JWatch General 2005;2005:2-2.
FULL TEXT
Coxibs, Science, and the Public Trust
Solomon and Avorn
Arch Intern Med 2005;165:158-160.
FULL TEXT
|
